Integra LifeSciences (NASDAQ:IART – Get Free Report) updated its second quarter earnings guidance on Monday. The company provided EPS guidance of $0.60-0.65 for the period, compared to the consensus EPS estimate of $0.74. The company issued revenue guidance of $411-416 million, compared to the consensus revenue estimate of $395.81 million. Integra LifeSciences also updated its FY 2024 guidance to 3.010-3.110 EPS.
Integra LifeSciences Stock Down 0.7 %
IART stock traded down $0.17 during trading on Wednesday, hitting $24.91. 1,907,390 shares of the company’s stock traded hands, compared to its average volume of 823,586. The business has a fifty day simple moving average of $32.95 and a two-hundred day simple moving average of $38.24. The company has a quick ratio of 2.18, a current ratio of 3.45 and a debt-to-equity ratio of 0.94. The firm has a market capitalization of $1.96 billion, a P/E ratio of 30.22, a PEG ratio of 0.87 and a beta of 1.17. Integra LifeSciences has a 1 year low of $22.36 and a 1 year high of $50.78.
Integra LifeSciences (NASDAQ:IART – Get Free Report) last released its quarterly earnings results on Monday, May 6th. The life sciences company reported $0.55 EPS for the quarter, hitting the consensus estimate of $0.55. Integra LifeSciences had a return on equity of 15.19% and a net margin of 4.39%. The firm had revenue of $368.90 million during the quarter, compared to analyst estimates of $361.96 million. During the same period in the previous year, the company posted $0.74 EPS. The business’s revenue for the quarter was down 3.2% compared to the same quarter last year. Sell-side analysts anticipate that Integra LifeSciences will post 3.19 EPS for the current year.
Analyst Upgrades and Downgrades
Get Our Latest Research Report on IART
Integra LifeSciences Company Profile
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.
Read More
- Five stocks we like better than Integra LifeSciences
- The 3 Best Blue-Chip Stocks to Buy Now
- Lucid’s Stock Price is Still in Reverse: New Lows Are Coming
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Generac Powers Ahead on the Electrification Mega-Trend
- ETF Screener: Uses and Step-by-Step Guide
- PulteGroup Wins and Wins More on Interest Rate Cuts
Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.